JP2003528919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528919A5 JP2003528919A5 JP2001572110A JP2001572110A JP2003528919A5 JP 2003528919 A5 JP2003528919 A5 JP 2003528919A5 JP 2001572110 A JP2001572110 A JP 2001572110A JP 2001572110 A JP2001572110 A JP 2001572110A JP 2003528919 A5 JP2003528919 A5 JP 2003528919A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aromatase inhibitor
- treatment
- previously
- tamoxifen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003886 aromatase inhibitor Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 3
- 229960001603 Tamoxifen Drugs 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229960002258 Fulvestrant Drugs 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
Description
【特許請求の範囲】
【請求項１】
アロマターゼ阻害剤およびタモキシフェンで以前に治療されて、当該治療で以前に失敗した患者における乳癌を処置するための、フルベストラントを含む医薬組成物。
【請求項２】
前記患者が、２種より多い異なるホルモン剤で以前に乳癌の処置を受けていない、請求項１に記載の医薬組成物。
【請求項３】
タモキシフェンでの処置がアロマターゼ阻害剤での処置に先行した、請求項１または２に記載の医薬組成物。
【請求項４】
アロマターゼ阻害剤が、アナストロゾール、レトロゾール又はアミノグルテチミドである、請求項１〜３のいずれか１項に記載の医薬組成物。
【請求項５】
アロマターゼ阻害剤がアナストロゾールである、請求項１〜４のいずれか１項に記載の方法。
【請求項６】
筋肉内注射により投与するための請求項１〜５のいずれか１項に記載の医薬組成物。
【請求項７】
アロマターゼ阻害剤およびタモキシフェンで以前に治療されて、当該治療で以前に失敗した乳癌患者を処置するための医薬品の調製におけるフルベストラントの使用。
【請求項１】
アロマターゼ阻害剤およびタモキシフェンで以前に治療されて、当該治療で以前に失敗した患者における乳癌を処置するための、フルベストラントを含む医薬組成物。
【請求項２】
前記患者が、２種より多い異なるホルモン剤で以前に乳癌の処置を受けていない、請求項１に記載の医薬組成物。
【請求項３】
タモキシフェンでの処置がアロマターゼ阻害剤での処置に先行した、請求項１または２に記載の医薬組成物。
【請求項４】
アロマターゼ阻害剤が、アナストロゾール、レトロゾール又はアミノグルテチミドである、請求項１〜３のいずれか１項に記載の医薬組成物。
【請求項５】
アロマターゼ阻害剤がアナストロゾールである、請求項１〜４のいずれか１項に記載の方法。
【請求項６】
筋肉内注射により投与するための請求項１〜５のいずれか１項に記載の医薬組成物。
【請求項７】
アロマターゼ阻害剤およびタモキシフェンで以前に治療されて、当該治療で以前に失敗した乳癌患者を処置するための医薬品の調製におけるフルベストラントの使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008172.9A GB0008172D0 (en) | 2000-04-05 | 2000-04-05 | Therapy |
| GB0008172.9 | 2000-04-05 | ||
| PCT/GB2001/001500 WO2001074366A1 (en) | 2000-04-05 | 2001-04-02 | Use of fulvestrant in the treatment of resistant breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528919A JP2003528919A (ja) | 2003-09-30 |
| JP2003528919A5 true JP2003528919A5 (ja) | 2008-05-08 |
Family
ID=9889101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572110A Pending JP2003528919A (ja) | 2000-04-05 | 2001-04-02 | 抵抗性乳癌の治療におけるフルベストラントの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20030158166A1 (ja) |
| EP (2) | EP1272195B1 (ja) |
| JP (1) | JP2003528919A (ja) |
| KR (1) | KR100757764B1 (ja) |
| CN (1) | CN1431905A (ja) |
| AT (1) | ATE306270T1 (ja) |
| AU (2) | AU2001244372B2 (ja) |
| BR (1) | BR0109789A (ja) |
| CA (1) | CA2403608A1 (ja) |
| CH (1) | CH1272195H1 (ja) |
| CZ (1) | CZ303096B6 (ja) |
| DE (1) | DE60113975T2 (ja) |
| DK (1) | DK1272195T3 (ja) |
| EE (1) | EE05026B1 (ja) |
| ES (1) | ES2248300T3 (ja) |
| GB (1) | GB0008172D0 (ja) |
| HK (1) | HK1051498A1 (ja) |
| HU (1) | HU230064B1 (ja) |
| IL (2) | IL151932A0 (ja) |
| IS (1) | IS2869B (ja) |
| MX (1) | MXPA02009744A (ja) |
| NO (1) | NO329949B1 (ja) |
| NZ (1) | NZ539603A (ja) |
| PL (1) | PL201175B1 (ja) |
| RU (1) | RU2265438C2 (ja) |
| SK (1) | SK287779B6 (ja) |
| UA (1) | UA80388C2 (ja) |
| WO (1) | WO2001074366A1 (ja) |
| ZA (1) | ZA200207538B (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003006064A1 (en) * | 2001-07-07 | 2003-01-23 | Astrazeneca Ab | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| EP1623713A1 (en) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Cominations of pure anti-estrogen with aromatase inhibitors |
| US8557863B2 (en) * | 2005-09-27 | 2013-10-15 | Robert Benson Aylor | Suppression and prevention of tumors |
| JP5256042B2 (ja) * | 2005-11-22 | 2013-08-07 | インサイト・コーポレイション | 癌の処置のための併用療法 |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| RU2013154048A (ru) * | 2011-05-09 | 2015-06-20 | Юниверсити Оф Вирджиния Пэтент Фаундейшн | Композиции и способы лечения рака |
| MX2013013558A (es) | 2011-05-20 | 2013-12-16 | Capital Business Y Gestion De Finanzas S L | Composicion farmaceutica. |
| EP3092027A4 (en) * | 2014-01-10 | 2017-09-06 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| US9421264B2 (en) * | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| CA3073836A1 (en) | 2017-09-11 | 2019-03-14 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
| JP7384903B2 (ja) * | 2018-05-24 | 2023-11-21 | ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | フルベストラントのプロドラッグ |
| CA3210276A1 (en) * | 2020-02-29 | 2021-09-02 | Frances E. Carr | Use of thyromimetics for the treatment of cancer |
-
2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
-
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en active IP Right Grant
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko active IP Right Grant
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
-
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
-
2003
- 2003-05-27 HK HK03103770A patent/HK1051498A1/xx not_active IP Right Cessation
-
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006501240A5 (ja) | ||
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| EP2338516A3 (en) | Multiple-variable dose regimen for treating TNF-alpha-related disorders | |
| TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
| EE200400020A (et) | Asendatud oksasolidinoonid kombineeritud raviks | |
| DE602004028841D1 (de) | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c | |
| TW200509956A (en) | Compositions and methods for treatment of rosacea | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| ATE457166T1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| JP2003528919A5 (ja) | ||
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
| SE0002754D0 (sv) | New pharmaceutical combination formulation and method of treatment with the combination | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| JP2004537500A5 (ja) | ||
| BR0112280A (pt) | Nova utilização para deferiprona | |
| RU2002129355A (ru) | Применение фульвестранта при лечении резистентного рака молочной железы | |
| RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
| DE60143078D1 (de) | Pax2 zur behandlung von nierenkrankheiten | |
| AR045263A1 (es) | Metodo, kit y composicion farmaceutica para tratar infecciones virales |